Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Markus Joerger, J A Burgers, P Baas, V D Doodeman, P H M Smits, R S Jansen, L D Vainchtein, H Rosing, A D R Huitema, J H Beijnen & J H M Schellens
Although the mutant CDA*2 allele results in an increased exposure to gemcitabine in Caucasian patients, this study gives no definite conclusion on the clinical relevance of this finding. Further studies should look into the relationship between CDA genotypes, plasmatic CDA activity, and clinical outcome in patients receiving gemcitabine-based chemotherapy.
|citation||Joerger M, Burgers J A, Baas P, Doodeman V D, Smits P H M, Jansen R S, Vainchtein L D, Rosing H, Huitema A D R, Beijnen J H, Schellens J H M. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.|
|type||journal paper/review (English)|
|date of publishing||18-05-2011|
|journal title||Cancer Chemother Pharmacol (69/1)|